Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG+MM trial in high-risk non-muscle-invasive bladder cancer
2020-000235-51Phase 3Unknown
- Sponsor
- Nottingham University Hospitals
- Start
- Oct 2020
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) comparing BCG + mitomycin-C with BCG alone (2 arms). Primary endpoint: Disease-free survival. Status: unknown.
02
Drugs
bcg vaccinemitomycin c
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2020-000235-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000235-51.